Abeona Therapeutics Says CMS Granted New Technology Add-On Payment Status For ZEVASKYN Under Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final Rule
The Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for ZEVASKYN (prademagene zamikeracel) under the Fiscal Year 2027 Hospital Inpatient Prospective Payment
A government health program said Abeona's new medicine ZEVASKYN can get extra payment money from hospitals starting next year. This means the company might make more money from this treatment, which shows the government thinks it's valuable enough to support.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.